- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Arch Biopartners Inc: Arch Biopartners 250,323-share private placement | 2 | Stockwatch | ||
| 11.11. | Arch Biopartners Inc: Arch Biopartners begins patient dosing for LSALT trial | 1 | Stockwatch | ||
| 11.11. | Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury | 51 | GlobeNewswire (Europe) | TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing have begun in... ► Artikel lesen | |
| 16.10. | Arch Biopartners Inc: Arch Biopartners arranges $450,000 private placement | 1 | Stockwatch | ||
| ARCH BIOPARTNERS Aktie jetzt für 0€ handeln | |||||
| 16.10. | Arch Biopartners Arranges Non-Brokered Private Placement | 1 | GlobeNewswire (USA) | ||
| 03.10. | Arch Biopartners Inc: Arch Biopartners closes units-for-debt settlement | 2 | Stockwatch | ||
| 03.10. | Arch Biopartners: Closes Units for Debt Settlement | 1 | GlobeNewswire (USA) | ||
| 26.09. | Arch Biopartners Inc: Arch Biopartners to issue units to settle debt | 3 | Stockwatch | ||
| 26.09. | Arch Biopartners: Units for Debt Settlement | 2 | GlobeNewswire (USA) | ||
| 11.09. | Arch Biopartners Inc: Arch Biopartners receives Alberta OK for phase II trial | 1 | Stockwatch | ||
| 11.09. | Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI) | 1 | GlobeNewswire (USA) | ||
| 07.08. | Arch Biopartners Inc: Arch Biopartners 400,000-share private placement | 1 | Stockwatch | ||
| 02.08. | Arch Biopartners Inc: Arch Biopartners' cilastatin to join Pontiac trial | 1 | Stockwatch | ||
| 02.08. | Arch Biopartners' Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins | 84 | GlobeNewswire (Europe) | Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI)Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its unique... ► Artikel lesen | |
| 30.07. | Arch Biopartners Closes Non-Brokered Private Placement | 1 | GlobeNewswire (USA) | ||
| 29.07. | Arch Biopartners Inc: Arch Biopartners arranges $600,000 private placement | 1 | Stockwatch | ||
| 29.07. | Arch Biopartners Arranges Non-Brokered Private Placement | 1 | GlobeNewswire (USA) | ||
| 27.06. | Arch Biopartners Inc: Arch Biopartners talks cilastatin GMP stages | 1 | Stockwatch | ||
| 27.06. | Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product | 1 | GlobeNewswire (USA) | ||
| 18.06. | Arch Biopartners Inc: Arch partner receives ethics OK for phase II trial | 2 | Stockwatch |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 8,500 | -15,59 % | Aktien KW 46 Trump-Verdauen. Neue Favoriten, Quartalsergebnisse - Gemengelage mit Licht und Schatten. Dazu Hoffen auf Jahresendrallye? News. Rheinmetall. Evotec. JDC. Mutares. Grammer. Hypoport. tonies. HomeToGo | Aktien Wochenrückblick - Fokus auf die "erwarteten" Folgen einer Präsidentschaft Trumps: Krypto's feiern neue Rekorde, China wird kritischer beäugt, wegen der bisher eher zögerlichen Konjunkturspritzen... ► Artikel lesen | |
| QIAGEN | 41,045 | +2,05 % | Qiagen NV-Aktie büßt 0,31 Prozent ein (39,06 €) | Im Minus liegt zur Stunde der Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 39,06 Euro. An der Börse liegt die Qiagen NV-Aktie aktuell im Minus. Das Papier verbilligte sich um 12 Cent. Das Wertpapier... ► Artikel lesen | |
| ARCELLX | 90,44 | +3,69 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| BIONTECH | 108,90 | +0,28 % | Kaufen oder Verkaufen?: Die spannende Zukunft von BioNTech, Pfizer & Co. | © Foto: SymbolbildAktien von BioNTech, Moderna und Pfizer geraten gerade ordentlich unter Druck - und das aus gutem Grund. Ex-Präsident Donald Trump hat einen überraschenden Schachzug gemacht, der die... ► Artikel lesen | |
| DYNE THERAPEUTICS | 29,690 | -0,27 % | Wissenschaftliche Leiterin von Dyne Therapeutics verkauft Aktien im Wert von 80.539 US-Dollar | ||
| KYMERA THERAPEUTICS | 44,980 | +3,38 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update | KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,695 | -0,96 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| KEROS THERAPEUTICS | 55,92 | +3,86 % | Keros Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | ||
| MODERNA | 39,575 | +0,18 % | Opening Bell: Tech-Aktien am Montag im Plus; Tesla, Palantir, Moderna, Netflix, Nvidia im ... | Nach den jüngsten Kursausschlägen im Zuge des Wahlsiegs von Donald Trump steuern die US-Börsen am Montag auf einen relativ ruhigen Wochenstart zu. Während der Dow Jones Industrial vom Broker IG eine... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,79 | +0,01 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| VERA THERAPEUTICS | 48,290 | +2,68 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 18, 2024, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,160 | -0,66 % | Adma Biologics CEO Adam Grossman verkauft Aktien im Wert von 1,03 Millionen US-Dollar | ||
| SPRINGWORKS THERAPEUTICS | 39,030 | +7,52 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| 4D MOLECULAR THERAPEUTICS | 7,790 | -2,50 % | 4D Molecular initiated by Morgan Stanley at underweight | ||
| RELAY THERAPEUTICS | 4,750 | +2,37 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights | Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer at RP2D Plan to initiate 2L pivotal trial of... ► Artikel lesen |
ARCH BIOPARTNERS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCH BIOPARTNERS INC finden Sie auf Wallstreet Online.
